AzTrials
AzTrials

Colon CancerNCT04780477

Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer

A study testing High Fiber Diet Featuring Legumes (HLD) and Healthy American Diet in people with Colon Cancer and Obesity, run by Emory University at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This study tests whether a high-fiber diet based on legumes, such as dry beans, can lead to sustained reductions in obesity and colon cancer risk in persons at highest risk, namely overweight or obese, post-polypectomy patients. Read more about this study

Who is it for?
Ages 40 to 75 years
Conditions the study is for
Colon Cancer, Obesity
What is being tested?
High Fiber Diet Featuring Legumes (HLD) and Healthy American Diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteUnited States
Study dates
29 Jun 2021to 30 Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • free-living adults 40 to 75 years old
  • BMI 25-40 kg/m^2
  • able to provide documentation confirming a colonoscopy within 3 years that found ≥1 adenoma >0.5 cm or a sessile serrated polyp (any)
  • English speaking
  • ambulatory, able to pick up food, participate in clinical exams and laboratory tests
  • able to provide informed consent

Who cannot join

  • serious and/or unstable medical condition as deemed by study physician
  • history of colorectal cancer, bowel resection, polyposis syndrome, or inflammatory bowel disease
  • smoked regularly in the past year
  • dietary restrictions substantially limiting compliance (e.g., must be willing to be randomized to either diet)
  • planning on substantially changing usual exercise behavior in the next 6 months
  • regular or recent use of prescription medication that may alter inflammation markers or gut function as deemed by study physician
  • pregnant women, breast feeding women, or women planning pregnancy within the year of active study participation

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Rollins School of Public Health, Emory University

    Atlanta, Georgia, 30322

Other trials in United States

About this study

This study tests whether a high-fiber diet based on legumes, such as dry beans, can lead to sustained reductions in obesity and colon cancer risk in persons at highest risk, namely overweight or obese, post-polypectomy patients.

Read the detailed description

An important knowledge gap concerns the role of fiber in sustaining reduced energy intake to simultaneously manage weight and influence human colorectal cancer risk. Epidemiologic studies have shown an association between a high fiber diet featuring legumes (HLD) and reduced obesity and lower risk for adenoma recurrence or colorectal cancer. There are many plausible mechanisms to explain why high-fiber diets, and especially a HLD, may reduce colorectal cancer risk. First, fiber is fermented by the colonic microbiota to produce short chain fatty acids (SCFA). The SCFA, butyrate, has a remarkable array of colonic mucosal health promoting, anti-inflammatory, and anti-neoplastic properties. Secondly, microbiota break down plant cell walls releasing phytochemicals, which also have powerful anti-inflammatory and anti-carcinogenic effects. Thirdly, colonic transit is accelerated, reducing contact time with luminal carcinogens, such as heterocyclic amines formed from cooked red meat, and secondary bile acids, induced by a high fat diet and synthesized by the colonic microbiota.

Dr. Stephen O'Keefe's lab performed a human randomized controlled crossover feeding study (participants receive both diets) comparing high and low- fiber diets. The study measured mucosal biomarkers of cancer risk (proliferation - % epithelial cells staining positive for Ki67, inflammation - cluster of differentiation 3 (CD3)+ intraepithelial lymphocytes, cluster of differentiation 68 (CD68)+ lamina propria macrophages) made by fecal sampling and colonoscopy. Results suggested that within weeks these markers responded favorably to the high-fiber diet with proliferative rates and inflammatory biomarkers decreasing and microbiota composition adapting to increase butyrogenesis.

The researchers of this study have previously found that fiber may also reduce cancer risk indirectly by promoting weight loss, improving insulin sensitivity and decreasing inflammation. On average, individuals consume a similar weight of food daily; thus, replacing energy dense foods (higher kcal/g, e.g., high fat) with lower energy density foods (lower kcal/g), like legumes, should potentiate weight control. Viscous fiber intake is associated with longer gastric emptying times which over time might contribute to postponing the next eating occasion. Diet may also induce changes in gut microbiome composition leading to negative energy balance. Emerging human evidence links the gut microbiome with insulin resistance, inflammation, and obesity and with adenomatous polyps and colon cancer. In this current study, characterizing gut motility, microbiome, and metabolome composition profiles that may influence weight loss and have a role in the prevention or recurrence of adenomas and colorectal cancer, will provide novel and potentially therapeutic information.

The goal of the research is to conduct a clinical trial featuring study-provided pre-portioned entrées and strategic nutritional instruction to guide participants to integrate legumes into a healthy high-fiber diet pattern. Participants will be provided two entrées per day during months 1 through 3, and one entrée per day during months 4 through 6. Participants will continue their diets during months 7 through 12 but will be responsible for food preparation. The research will target a population at high risk for colorectal cancer, overweight and obese participants with a history of a colon polyp in the past 3 years, to test whether a high-legume, high-fiber diet will simultaneously increase weight loss and suppress intestinal biomarkers of cancer risk compared to a control diet (healthy American). In addition, it will explore potential mechanisms through which the high-legume intervention diet facilitates weight loss and intestinal health.

Being tested
High Fiber Diet Featuring Legumes (HLD), Healthy American Diet
Keywords
Fiber-rich Foods, Legumes, Weight loss, Intestinal health, Cancer prevention
Medical subject headings
Colonic Neoplasms, Obesity, Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High Fiber Diet Featuring Legumes (HLD)Dietary supplement

    The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. ~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.

  • Healthy American DietDietary supplement

    The healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.

Study groups in NCT04780477
Study groupRoleWhat they receive
High Fiber Diet Featuring Legumes (HLD)ExperimentalParticipants randomized to the high fiber diet featuring legumes (HLD) will add approximately 30 grams of dietary fiber per day from legume dishes, ensuring a total intake of approximately 50 grams of dietary fiber per day.
Receives: Dietary Supplement: High Fiber Diet Featuring Legumes (HLD)
Healthy American Diet Control ArmActive comparatorParticipants randomized to the healthy American diet control arm will receive pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat.
Receives: Dietary Supplement: Healthy American Diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Body Weight

    Body weight is measured (in pounds) on a regularly calibrated digital scale while wearing light clothing without shoes.

    Measured: Baseline, Month 6 (end of intense intervention)

  2. Change in Ki-67+ Level

    Mucosal biopsies are obtained to measure the colonic mucosal proliferative biomarker Ki-67+.

    Measured: Baseline, Month 6 (end of intense intervention)

Secondary outcomes (8)
  1. Change in Body Weight During Maintenance Period

    Body weight is measured (in pounds) on a regularly calibrated digital scale while wearing light clothing without shoes.

    Measured: Month 6, Month 12

  2. Change in Ki-67+ Level During Maintenance Period

    Mucosal biopsies are obtained to measure the colonic mucosal proliferative biomarker Ki-67+.

    Measured: Month 6, Month 12

  3. Change in Gut Transit Time

    Gut transit time is assessed using an indigestible single-use SmartPill capsule, a receiver, and display software. The SmartPill capsules were discontinued and no longer available after 2023 so participants beginning after January 19, 2024 will not complete this assessment.

    Measured: Baseline, Month 6 (end of intense intervention)

  4. Change in Fasting Plasma Insulin Level

    Fasting plasma insulin, a biomarker of insulin resistance, is measured by blood test.

    Measured: Baseline, Month 6, Month 12

  5. Change in Fasting Plasma Glucose Level

    Fasting plasma glucose, a biomarker of insulin resistance, is measured by blood test.

    Measured: Baseline, Month 6, Month 12

  6. Change in Serum C-reactive Protein

    Serum C-reactive protein, an indicator of systemic inflammation, is measured by blood test.

    Measured: Baseline, Month 6, Month 12

  7. Change in CD3+ Intraepithelial Lymphocytes Count

    CD3+ intraepithelial lymphocytes, a colonic mucosal inflammatory biomarker of colon cancer risk, is measured by mucosal biopsy.

    Measured: Baseline, Month 6, Month 12

  8. Change in CD68+ Lamina Propia Macrophages Count

    CD68+ lamina propia macrophages, a colonic mucosal inflammatory biomarker of colon cancer risk, is measured by mucosal biopsy.

    Measured: Baseline, Month 6, Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2021
  2. Study start29 Jun 2021
  3. Primary completion29 May 2025
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04780477
Sponsor's protocol ID
STUDY00000563
Other IDs
R01CA245063
Status last verified
Aug 2026
First submitted
2 Mar 2021
Last updated
20 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified participant phenotypic data will be made available for sharing but limited to health/biomedical purposes including age, obesity status, presence of colon polyps and history of diabetes. The data will be coded and only the coded data set, and not the master list, will be shared.

Publications

  • Hartman TJ, Christie J, Wilson A, Ziegler TR, Methe B, Flanders WD, Rolls BJ, Loye Eberhart B, Li JV, Huneault H, Cousineau B, Perez MR, O'Keefe SJD. Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer trial study protocol: a randomised clinical trial of fibre-rich legumes targeting the gut microbiome, metabolome and gut transit time of overweight and obese patients with a history of noncancerous adenomatous polyps. BMJ Open. 2024 Feb 5;14(2):e081379. doi: 10.1136/bmjopen-2023-081379.

    PubMed 38316601

Questions about this trial

What is this clinical trial studying?

A study testing High Fiber Diet Featuring Legumes (HLD) and Healthy American Diet in people with Colon Cancer and Obesity, run by Emory University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Body Weight (time frame: Baseline, Month 6 (end of intense intervention)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04780477, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in